Alnylam Pharmaceuticals Inc (ALNY)
268.23
-1.70
(-0.63%)
USD |
NASDAQ |
Nov 05, 09:50
Alnylam Pharmaceuticals Cash from Investing (Quarterly): -30.25M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -30.25M |
| June 30, 2024 | 33.94M |
| March 31, 2024 | -67.62M |
| December 31, 2023 | -240.66M |
| September 30, 2023 | -10.76M |
| June 30, 2023 | -8.713M |
| March 31, 2023 | -76.22M |
| December 31, 2022 | -139.91M |
| September 30, 2022 | 313.89M |
| June 30, 2022 | 142.79M |
| March 31, 2022 | -147.42M |
| December 31, 2021 | -413.40M |
| September 30, 2021 | -88.27M |
| June 30, 2021 | 157.02M |
| March 31, 2021 | 71.35M |
| December 31, 2020 | -97.89M |
| September 30, 2020 | -10.09M |
| June 30, 2020 | -441.23M |
| March 31, 2020 | 113.69M |
| December 31, 2019 | -220.85M |
| September 30, 2019 | -10.08M |
| June 30, 2019 | -289.40M |
| March 31, 2019 | 102.65M |
| December 31, 2018 | 248.96M |
| September 30, 2018 | 96.17M |
| Date | Value |
|---|---|
| June 30, 2018 | 62.62M |
| March 31, 2018 | -134.81M |
| December 31, 2017 | -160.59M |
| September 30, 2017 | -137.18M |
| June 30, 2017 | -67.67M |
| March 31, 2017 | 75.08M |
| December 31, 2016 | 100.39M |
| September 30, 2016 | -31.40M |
| June 30, 2016 | -44.34M |
| March 31, 2016 | 117.94M |
| December 31, 2015 | 78.27M |
| September 30, 2015 | 48.67M |
| June 30, 2015 | -106.94M |
| March 31, 2015 | -341.33M |
| December 31, 2014 | 21.44M |
| September 30, 2014 | 37.91M |
| June 30, 2014 | -228.38M |
| March 31, 2014 | -379.78M |
| December 31, 2013 | 56.05M |
| September 30, 2013 | -2.504M |
| June 30, 2013 | -53.21M |
| March 31, 2013 | -130.84M |
| December 31, 2012 | 43.51M |
| September 30, 2012 | 17.85M |
| June 30, 2012 | 7.601M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-441.23M
Minimum
Jun 2020
313.89M
Maximum
Sep 2022
-58.03M
Average
-48.94M
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc | 4.60B |
| Regeneron Pharmaceuticals Inc | -574.40M |
| BridgeBio Pharma Inc | 3.039M |
| Biomarin Pharmaceutical Inc | -16.16M |
| Johnson & Johnson | -3.128B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 43.71M |
| Cash from Financing (Quarterly) | 102.76M |
| Free Cash Flow | 16.06M |
| Free Cash Flow Per Share (Quarterly) | 0.3073 |
| Free Cash Flow to Equity (Quarterly) | 38.55M |
| Free Cash Flow to Firm (Quarterly) | 41.80M |
| Free Cash Flow Yield | 0.05% |